Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
Toggle Summary Agile Therapeutics Appoints Chief Financial Officer
Dennis P. Reilly to bring commercial experience to management team Appointment Effective August 5, 2019 PRINCETON, N.J. , July 18, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Dennis P....
Toggle Summary Agile Therapeutics Appoints Ajit S. Shetty, Ph.D., to Its Board of Directors
Andrew Schiff, M.D. to Step Down From the Board...
Toggle Summary Agile Therapeutics Applauds Congressional Chairs’ Letter to Biden Administration Requesting Enforcement of Contraceptive Access Under Affordable Care Act
PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today applauded House Congressional Committee leaders in urging the Secretaries of U.S. Departments of Health and Human Services (HHS), Treasury, and Labor to enforce the law...
Toggle Summary Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020
Company to Present Twirla ® Commercial Plan Webcast Scheduled from 11:00 am – 1:00 pm EDT PRINCETON, N.J. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will host a virtual Investor/Analyst Day on Monday, September...
Toggle Summary Agile Therapeutics Announces Three New U.S. Patents on Its Technology and the Brand Name Twirla™ for Its First Contraceptive Patch
Toggle Summary Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of MMCAP Infuse, effective July 1, 2023 MMCAP Infuse has over 26,000 member facilities in all 50 states Impact of availability to MMCAP Infuse is expected to augment future non-retail...
Toggle Summary Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch dispensed within FPA clinics in California Impact of availability through FPA Women’s Health is...
Toggle Summary Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
Confirms Plans to Re-submit New Drug Application for Twirla® by the end of the Second Quarter of 2017...
Toggle Summary Agile Therapeutics Announces Reorganization of Leadership Team
Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth Company Streamlines Leadership Team to Align with Plan to Grow Twirla ® James Tursi, M.D. Resigns from Board of Directors PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
Shadow